OMedLive

CME Presentations

Ovarian Cancer


Presentations


Speakers

  • Shannon N. Westin, MD, MPH, FACOG

    Shannon N. Westin, MD, MPH, FACOG

    Shannon N. Westin, MD, MPH, FACOG

    Associate Professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery

    Shannon N. Westin, MD, MPH, is an associate professor in the Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, at the University of Texas, MD Anderson Cancer Center in Houston. Dr Westin focuses on developmental therapeutics and the use of biomarkers to predict response and recurrence in gynecologic malignancies. She is the director of Early Drug Development and Phase I trials and serves on the NRG Oncology – GOG Developmental Therapeutics and Phase I committees. She is co-PI for major projects in her institution’s SPORE in uterine cancer and SPORE in ovarian cancer, and serves as the PI or co-PI for more than 20 novel treatment trials in gynecologic malignancies. Dr Westin received her MD from the University of Florida College of Medicine in Gainesville.
  • Judith A. Smith, BS, PharmD, BCOP, CPHQ, FCCP, FISOPP

    Judith A. Smith, BS, PharmD, BCOP, CPHQ, FCCP, FISOPP

    Judith A. Smith, BS, PharmD, BCOP, CPHQ, FCCP, FISOPP

    Associate Professor

    Judith A. Smith, PharmD, BCOP, CPHQ, FCCP, FISOPP, BS, is an associate professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of Texas Health McGovern Medical School in Houston, and the director of the Women’s Health Integrative Medicine Program. Dr Smith’s research mission is to advance the progress of the safe and effective use of nutritional and herbal supplements with pharmacologic modalities as it relates to women’s health and cancer through innovative thinking, systematic methodology, and collaborative interactions throughout the UTHealth System and global research community. She received her Doctor of Pharmacy and Bachelor of Science in Pharmacy from Albany College of Pharmacy of Union University in Albany, New York.
  • Robert L. Coleman, MD, FACOG, FACS

    Robert L. Coleman, MD, FACOG, FACS

    Robert L. Coleman, MD, FACOG, FACS

    Professor and Vice Chair of Clinical Research, Department of Gynecologic Oncology and Reproductive Medicine

    Robert L. Coleman, MD, FACOG, FACS, is a professor, vice chair of clinical research, and the Ann Rife Cox Chair in Gynecology in the Department of Gynecologic Oncology and Reproductive Medicine at the University of Texas MD Anderson Cancer Center in Houston. His research interests include drug discovery and novel therapeutics for ovarian, uterine and cervical cancer, clinical trial development and statistical design, and he serves as a principal investigator (PI) or co-PI for several prospective clinical trials. Dr Coleman is the author or co-author of more than 400 scientific publications, including over 250 peer-reviewed articles, numerous book chapters, monographs, invited articles and textbooks. He received his medical degree from Creighton University in Omaha, Nebraska.

CME Information

PARP in Practice: Expanding Options in the Maintenance Setting for Ovarian Cancer


LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

  • Integrate the latest maintenance setting data on PARP inhibitors into patients’ treatment algorithms
  • Formulate management plans for adverse events associated with PARP inhibitors in the maintenance setting
  • Review emerging strategies with PARP inhibitors in the frontline, maintenance setting

Acknowledgement

This activity is supported by educational grants from Clovis Oncology, Inc. AstraZeneca, and TESARO.

Tuition

Complimentary

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statements

Physician Continuing Education
Live Internet Activity

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Date of Release/Expiration

Live Activity
December 20, 2018 from 1:00pm – 2:00pm ET.

Enduring Material
The enduring material will be available from December 20, 2018 to December 20, 2019.

Target Audience

This activity is intended for gynecologic, medical, surgical and radiation oncologists, oncology nurses, nurse practitioners, pharmacists, gynecologists, primary care physicians, physician assistants, and other HCPs who are interested/involved in the therapeutic management of patients with ovarian cancer.

Estimated Time to Complete

This activity consists of one session which should take approximately 1 hour to complete.

Method of Participation

There are no fees to participate in this activity. To participate in the activity, go to www.OMedlive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

Hardware/Software Requirements

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Financial Disclosures

Presenters

Shannon N. Westin, MD, MPH, FACOG
Associate Professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery
The University of Texas MD Anderson Cancer Center
Physician, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery
Lyndon Baines Johnson Hospital

Consulting Fees: AstraZeneca, Clovis, Medivation, Merck, Ovation, Pfizer, Roche/Genentech, Takeda, Tesaro
Contracted Research: AstraZeneca, Bayer, Clovis, Cotinga Pharmaceuticals, Roche/Genentech, Tesaro

Robert L. Coleman, MD, FACOG, FACS
Professor & Executive Director, Cancer Network Research, Department of Gynecologic Oncology & Reproductive Medicine
Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas MD Anderson Cancer Center

Consulting Fees: AbbVie, Agenus, AstraZeneca, Clovis, Gamamab, Genmab A/S, ImmunoGen, Merck, Oncolytics, Perthera, Roche/Genentech, Tesaro
Contracted Research: AstraZeneca, City of Hope Foundation, Clovis Oncology, Gateway Foundation, Genentech, Janssen, Merck, Novartis, V-Foundation

Judith A. Smith, BS, PharmD, BCOP, CPHQ, FCCP, FISOPP
Associate Professor
Director of Women’s Health Integrative Medicine Research Program, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology & Reproductive Sciences
McGovern Medical School at UTHealth

Consulting Fees: Clovis Oncology, Pfizer Oncology
Other travel reimbursement: Tesaro

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Financial Disclosures

Hamsa Jaganathan, PhD
Medical Director
PlatformQ Health Education, LLC

None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Elizabeth del Nido, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unapproved/Off Label Use (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Discalimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

Accreditation Support:
Please contact the Postgraduate Institute for Medicine at www.pimed.com

Technical Support:
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com